Provided by Tiger Fintech (Singapore) Pte. Ltd.

Merus NV

44.36
+2.536.05%
Post-market: 44.360.00000.00%19:49 EDT
Volume:1.00M
Turnover:43.15M
Market Cap:3.06B
PE:-13.23
High:44.44
Open:42.61
Low:41.56
Close:41.83
Loading ...

Merus Says US FDA Grants Breakthrough Therapy Designation to Petosemtamab

MT Newswires Live
·
18 Feb

Merus’ petosemtamab granted Breakthrough Therapy designation by FDA

TIPRANKS
·
18 Feb

Merus to Present at Citi's 2025 Virtual Oncology Leadership Summit

GlobeNewswire
·
13 Feb

Piper Sandler Initiates Merus at Overweight With $84 Price Target

MT Newswires Live
·
13 Feb

Analyst Recommends Buy for Merus Based on Promising Petosemtamab Developments and Revenue Potential

TIPRANKS
·
13 Feb

Merus initiated with an Overweight at Piper Sandler

TIPRANKS
·
13 Feb

Wells Fargo Initiates Merus at Overweight With $91 Price Target

MT Newswires Live
·
07 Feb

New England Journal of Medicine Publishes: Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer

GlobeNewswire
·
06 Feb

Bank of America Securities Sticks to Its Buy Rating for Merus (MRUS)

TIPRANKS
·
14 Jan

Biohaven enters multi-target collaboration with Merus

TIPRANKS
·
14 Jan

Merus, Biohaven Partner to Develop Bispecific Therapies for Cancers

MT Newswires Live
·
13 Jan

Jim Cramer Says Merus (MRUS) Still ‘Very Speculative’

Insider Monkey
·
08 Jan

Merus Reports First Person Dosed in Mid-Stage Petosemtamab Trial

MT Newswires Live
·
17 Dec 2024

Merus doses first patient in petosemtamab trial

TIPRANKS
·
17 Dec 2024

Merus announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 3L+ mCRC

GlobeNewswire
·
17 Dec 2024

GILD Obtains Positive CHMP Opinion for Liver Disease Drug

Zacks
·
17 Dec 2024

Merus (MRUS): FDA Approval and Speculative Future in Cancer Therapy

Insider Monkey
·
11 Dec 2024

Merus price target raised to $97 from $89 at Citi

TIPRANKS
·
10 Dec 2024

Stifel Nicolaus Sticks to Their Buy Rating for Merus (MRUS)

TIPRANKS
·
09 Dec 2024

Analysts Offer Insights on Healthcare Companies: Geron (GERN), Merus (MRUS) and C4 Therapeutics (CCCC)

TIPRANKS
·
09 Dec 2024